Article 14(1) of the Law of 2 May 2007 on the disclosure of large shareholders in issuers whose shares are admitted to trading on a regulated marketGhent, BELGIUM, June 16, 2025 (GLOBE NEWSWIRE) -- Press release - regulated information Biotalys NV (Euronext Brussel : BTLS) (the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, announces today, in accordance with article 14 of the Act of 2 May 2007 on the discl ...

US EPA projects taking a regulatory decision by end of September 2025; Dutch authorities finalise first phase of regulatory dossier for EVOCA in EuropeGhent, BELGIUM, June 11, 2025 (GLOBE NEWSWIRE) -- Press release Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, is pleased to announce progress in the regulatory approval procedures in both the United States and Europe of its first protein-based biocontrol product, E ...

Core Viewpoint - Biotalys has appointed Luc Van fraeyenhoven as the new Chief Financial Officer (CFO) to lead finance operations as the company advances its product pipeline towards commercialization [2][4]. Company Overview - Biotalys is an Agricultural Technology (AgTech) company focused on developing protein-based biocontrol solutions aimed at providing alternatives to conventional chemical pesticides for sustainable crop protection [5]. - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates targeting key crop pests and diseases [5]. - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021 and is based in Ghent, Belgium [5]. Leadership Transition - Luc Van fraeyenhoven, with over three decades of financial experience, will succeed Douglas Minder as CFO [2][3]. - Van fraeyenhoven has held CFO positions in various biotechnology and medtech companies, including Arseus Medical and ActoBio Therapeutics, and has significant experience in finance operations and strategy [3]. - The transition is expected to occur over the next few months, with Van fraeyenhoven expressing eagerness to contribute to Biotalys' innovative technology [2][4]. Strategic Importance - The appointment of Van fraeyenhoven is seen as crucial for Biotalys as it seeks to commercialize its first products while managing resources effectively [4]. - The leadership change is anticipated to enhance financial guidance on both long-term strategies and daily operations [4].